Allakos (ALLK) Stock Price, News & Analysis

Company Overview

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key Stats

• Today's Range: $1.03 to $1.31
• 50-Day Range: $0.54 to $1.34
• 52-Week Range: $0.54 to $3.41
• Volume: 3.31 million shs
• Average Volume: 846,858 shs
• Market Capitalization: $92.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.67
• Consensus Rating: Hold

Allakos Stock Analysis - MarketRank™

Allakos scored higher than 83% of companies evaluated by MarketBeat, and ranked 188th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Allakos has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Allakos has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Allakos are expected to grow in the coming year, from ($1.20) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allakos is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allakos is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Allakos has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.25% of the outstanding shares of Allakos have been sold short.

Short Interest Ratio / Days to Cover

Allakos has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Allakos has recently increased by 1.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allakos does not currently pay a dividend.

Dividend Growth

Allakos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.86

Percentage of Shares Shorted

2.25% of the outstanding shares of Allakos have been sold short.

Short Interest Ratio / Days to Cover

Allakos has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Allakos has recently increased by 1.53%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Allakos has a news sentiment score of -0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Allakos this week, compared to 1 article on an average week.

Search Interest

8 people have searched for ALLK on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allakos insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.12% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALLK Stock Analysis - Frequently Asked Questions

How have ALLK shares performed this year?

Allakos' stock was trading at $2.73 at the beginning of 2024. Since then, ALLK shares have decreased by 61.5% and is now trading at $1.05.
View the best growth stocks for 2024 here.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.02.

When did Allakos IPO?

Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allakos investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 10/23/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ALLK
• CUSIP: N/A
• CIK: 1564824
• Web: www.allakos.com
• Phone: (650) 597-5002
• Fax: N/A
• Employees: 131
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.67
• High Stock Price Target: $3.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +58.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-185,700,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -123.58%
• Return on Assets: -82.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.57
• Quick Ratio: 3.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.93 per share
• Price / Book: 0.54

Miscellaneous

• Outstanding Shares: 88,544,000
• Free Float: 74,528,000
• Market Cap: $92.97 million
• Optionable: Optionable
• Beta: 1.16